secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0000950170-23-007720
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx CMO Bedrosian transitions to advisor; Crombez named new CMO
----------------------------------------------------------------------

- Camille Bedrosian transitions to Strategic Development Advisor effective May 1, 2023.
- Eric Crombez promoted to EVP, Chief Medical Officer, effective May 1, 2023.
- Bedrosian’s new base salary set at $500,000; target bonus 35%; equity award of 6,900 RSUs and 9,200 options.
- Severance benefits under amended Offer Letter based on current $600,000 salary and 50% target bonus if termination before May 2024.
- Transition is planned, not a sudden departure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/0000950170-23-007720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017023007720/rare-20230314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer